CAS: 172889-27-9; 1-(Tert-Butyl)-3-(4-Chlorophenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine
该化合物是一种小分子化合物,以其作为弧离子细胞家族的选择性抑制器的作用而著称,它涉及各种细胞过程,包括扩散,区别和生存;该化合物的特点是它能够干扰有ATP约束作用的弧离子细胞站,从而抑制它们的活动;这种抑制可导致与癌症进化和转移有关的信号路径的调控;PP2 经常用于研究环境中的弧离子细胞行为的影响,并探索癌症治疗中的潜在治疗应用;该化合物通常在体外施用,并显示会影响各种细胞功能,包括移徙和入侵;其化学结构包括有助于其结合的紧凑性和选择性的特定的功能组;与许多动脉抑制剂一样,PP2的使用也可能与非目标效果有关,因此需要仔细解释实验结果.
- 英文名称1-(Tert-Butyl)-3-(4-Chlorophenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine
- 中文名称3-(4-氯苯基) 1-(1,1-二甲基乙基)-1H-吡唑并[3,4-d]嘧啶-4-胺
- IUPAC名称1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 其它别名PP 2; PP 2 (enzyme inhibitor)
- CAS编号172889-27-9
- MFCD编号:MFCD01568210
- EINECS号:878-892-3
- FDA UNII编号:PK8JPC58XB
- 分子式:C15H16ClN5
- 分子量:301.78
- 产品CID: 884462
- 产品分类生物化工 → 抑制剂 → 血管生成(Angiogenesis)
物理性质
- 熔点214-216 °C
- 沸点493.5±40.0 °C at 760 mmHg
- 闪点252.3±27.3 °C
- 密度1.4±0.1 g/cm3
- pKa:3.96±0.30(预测)
- PSA:69.62
- LogP:3.22
- 折射率1.676
- 蒸汽压0.0±1.3 mmHg at 25°C
- 溶解性Soluble In DMSO (Up To 25 mg/mL) Or In Ethanol (Up To 3 mg/mL With Warming).
- 外观形态类白色类白色固体
- 储存条件2-8°C
- 产品应用该化合物用于:分析在IQ域域GTPASE活性蛋白1(IQGGAP1)上信号的螺旋/焦粘粘合性血管酶(FAK)的影响,通过抗弧阻抗性媒介抗力,研究其对上皮瘤生长因受体(EGFR)和核因子红细胞2相关因子2(NRF2)对非小型细胞肺癌细胞细胞细胞中SRC在MDA-MB-231乳癌细胞中进行药理抑制的细胞的磷酸化作用
MSDS等安全信息
欧盟法规
C&L通报上下游产品
1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 4-Chlorophenylboronic acid 5-amino-1-(tert-butyl)-1H-pyrazole-4-carbonitrile合成工艺路线路线简述
5-氨基-4-氰基-1-叔丁基吡唑置于tris(Dibenzylideneacetone)Dipalladium(0) Chloroform Complex,溴,Caesium Carbonate,1,3,5,7-四甲基-6-苯基-2,4,8-三氧杂-6-磷酰金刚烷体系中,用 水,甲苯 用作溶剂,化学反应 3.0H,反应生成伐地考昔
参考文献:Microwave-Assisted Synthesis Of N1-And C3-Substituted Pyrazolo[3,4-D]Pyrimidine Libraries
标题:Microwave-Assisted Synthesis Of N1-And C3-Substituted Pyrazolo[3,4-D]Pyrimidine Libraries
摘要:The Parallel Synthesis Of A Library N1-And C3-Substituted-Pyrazolo[3,4-D]Pyrimidines Is Described. The Microwave-Assisted Approach Involves The De Novo Generation Of The Heterocyclic Scaffold,Facile Alkylation At N1 Via Either A Mitsunobu Or A Direct Alkylation Reaction And Arylation At C3 Via A Suzuki Reaction. (C) 2011 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Tetlet.2011.08.103
海关参考信息
- 2903919090-氯苯
- 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.
网址: http://www.pharm-intermediates.com
企业联系电话：0576-88813233👤
地址:台州市开发大道东段288号
企业联系电话：0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人：金崇光
电话：0576-88813233
手机：13396860566
传真：0576-88813233
邮箱：sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
电话：0576-88813233
手机：13396860566
传真：0576-88813233
邮箱：sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。
第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Seltana A, Guezguez A, Lepage M, Basora N, Beaulieu JF. Src family kinase inhibitor PP2 accelerates differentiation in human intestinal epithelial cells. Biochem Biophys Res Commun. 2012 Dec 27. doi:pii: S0006-291X(12)02433-3. 10.1016/j.bbrc.2012.12.085. [Epub ahead of print] doi: 10.1189/jlb.0911447. Epub 2012 Jul 11.
3: Bartscht T, Lehnert H, Gieseler F, Ungefroren H. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells. Cancer Chemother Pharmacol. 2012 Aug;70(2):221-30. doi: 10.1007/s00280-012-1904-0. Epub 2012 Jun 15. doi: 10.1016/j.biortech.2012.05.024. Epub 2012 May 12. doi: 10.1038/leu.2011.390. Epub 2011 Dec 19.
7: Ahn JH, Lee M. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett. 2011 Nov 28;310(2):188-97. doi: 10.1016/j.canlet.2011.06.034. Epub 2011 Jul 3. doi: 10.1007/s11010-010-0632-1. Epub 2010 Nov 4. doi: 10.1007/s00383-010-2775-2. doi: 10.1016/j.febslet.2010.06.002. Epub 2010 Jun 10. doi: 10.1104/pp.110.153882. Epub 2010 May 4.
合成参考文献
参考文献:10.1016/s0969-2126(99)80086-0
摘要:Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure. 1999 Jun 15;7(6):651–61. doi: 10.1016/s0969-2126(99)80086-0.
参考文献:10.1021/tx900365u
摘要:Nemec AA, Zubritsky LM, Barchowsky A. Chromium(VI) stimulates Fyn to initiate innate immune gene induction in human airway epithelial cells. Chem Res Toxicol. 2010 Feb 15;23(2):396–404.
参考文献:10.1074/jbc.m114.576249
摘要:Lee GH, Chhangawala Z, von Daake S, Savas JN, Yates JR, Comoletti D, D'Arcangelo G. Reelin Induces Erk1/2 Signaling in Cortical Neurons Through a Non-canonical Pathway. Journal of Biological Chemistry. 2014 Jul;289(29):20307–17. doi: 10.1074/jbc.m114.576249.
参考文献:10.1007/s12020-021-02907-7
摘要:Cheng P, Zhang X, Wang X, Liu C, Zhao X, Fan J, Xu C. Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src. Endocrine. 2022 Feb;75(2):635–45. doi: 10.1007/s12020-021-02907-7.
📝 需求与反馈
尽可能描述清楚需求与问题信息
